ExodusPoint Capital Management’s Nurix Therapeutics NRIX Stock Holding History

ExodusPoint Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$969K	Buy	+62,503	New	+$1.04M	0.01%	1014
2025 Q4	–	Sell	-130,130	Closed	-$1.2M	–	1902
2025 Q3	$1.2M	Sell	130,130 -63,364	-33%	-$658K	0.01%	896
2025 Q2	$2.2M	Buy	193,494 +174,326	+909%	+$1.88M	0.02%	714
2025 Q1	$228K	Sell	19,168 -66,494	-78%	-$1.11M	﹤0.01%	1278
2024 Q4	$1.61M	Buy	85,662 +51,049	+147%	+$1.17M	0.01%	795
2024 Q3	$778K	Sell	34,613 -285,939	-89%	-$6.48M	﹤0.01%	1048
2024 Q2	$6.69M	Buy	320,552 +154,949	+94%	+$2.41M	0.05%	324
2024 Q1	$2.43M	Sell	165,603 -132,166	-44%	-$1.42M	0.02%	625
2023 Q4	$3.07M	Buy	297,769 +247,621	+494%	+$1.7M	0.02%	454
2023 Q3	$394K	Buy	50,148 +8,430	+20%	+$77K	﹤0.01%	1320
2023 Q2	$417K	Buy	+41,718	New	+$425K	﹤0.01%	1421
2022 Q4	–	Sell	-25,954	Closed	-$338K	–	1965
2022 Q3	$338K	Buy	+25,954	New	+$411K	﹤0.01%	1491
2022 Q2	–	Sell	-15,034	Closed	-$211K	–	2281
2022 Q1	$211K	Buy	+15,034	New	+$267K	﹤0.01%	1888
2021 Q4	–	Sell	-10,747	Closed	-$322K	–	2468
2021 Q3	$322K	Buy	+10,747	New	+$332K	﹤0.01%	1589

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

ExodusPoint Capital Management's NRIX Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 62,503 shares worth $969K. The stake represents 0.01% of the portfolio and ranks #1014 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in NRIX as recently as Q3 2025.

ExodusPoint Capital Management first reported a position in NRIX in Q3 2021 and has held it in 14 quarters since. The position peaked at $6.69M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

ExodusPoint Capital Management held 62,503 shares of Nurix Therapeutics worth $969K as of Q1 2026.
Nurix Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
Nurix Therapeutics made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1014 holding.
ExodusPoint Capital Management first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 14 quarters since.
ExodusPoint Capital Management's Nurix Therapeutics position peaked at $6.69M in Q2 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.